Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.34 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.34 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7086867 | 0.80 | CSNK1A1 (0.39) | CSNK1A1TYRO3DYRK1BKDM4EALDH1A1 | |
| SCHEMBL1303712 | 0.73 | CSNK1A1 (0.37) | CSNK1A1TYRO3DYRK1BKDM4EALDH1A1 | |
| SCHEMBL28470761 | 0.70 | CSNK1A1 (0.35) | CSNK1A1TYRO3DYRK1BKDM4EALDH1A1 | |
| SCHEMBL16448086 | 0.69 | TAAR1 (0.35) | CSNK1A1TYRO3DYRK1BKDM4EALDH1A1 | |
| SCHEMBL27467097 | 0.67 | CSNK1A1 (0.42) | CSNK1A1TYRO3DYRK1BCA1CA2 | |
| SCHEMBL31169778 | 0.66 | ALDH1A1 (0.39) | CSNK1A1TYRO3DYRK1BKDM4EALDH1A1 | |
| SCHEMBL29053330 | 0.66 | CSNK1A1 (0.41) | CSNK1A1TYRO3DYRK1BCA1CA2 | |
| SCHEMBL28717458 | 0.64 | KLK1 (0.34) | CSNK1A1TYRO3DYRK1BALDH1A1 | |
| SCHEMBL3684538 | 0.63 | ALDH1A1 (0.38) | KDM4EALDH1A1 | |
| SCHEMBL391774 | 0.63 | ALDH1A1 (0.37) | CSNK1A1TYRO3DYRK1BKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040006118-A1 | Nf-kb inhibitors | SMITHKLINE BEECHAM CORPORATION | 2004-01-08 | — | — | US | disclosed |
| EP-1328272-A1 | NF-KAPPA-B INHIBITORS | SmithKline Beecham Corporation (US) | 2003-07-23 | — | — | EP | disclosed |
| WO-2002030423-A1 | NF-λB INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2002-04-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040006118-A1 | Nf-kb inhibitors | NFKBIA, IKBKB, IKBKG | CSNK1A1 190/4885TYRO3 905/4885DYRK1B 592/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.